A second, smaller syringe (typically a 1ml U-100 insulin syringe) is used for precise measurement and administration in your research model
By intention to treat analysis (n=8, 12 months), at 3, 6 and 12 months compared to baseline, weight loss was 6.8 4.1 kg, 10.0 5.6 kg and 8.9 8.4 kg (p=0.026)
Treatment significantly attenuated both clinical and histological signs of arthritis
Quick Answer: GLP-1 receptor agonists have not been definitively shown to directly cause clinically significant bone density loss, though the substantial weight reduction they produce may indirectly affect bone metabolism
When diabetic patients, especially the elderly, attempt to fill their GLP-1 prescription with drug plans such as Medicare Parts B and D, they are often met with deductibles of hundreds of dollars